Market Closed -
London S.E.
11:35:07 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
228.5
GBX
|
+3.86%
|
|
+12.56%
|
+3.86%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
467.4
|
495.7
|
847.6
|
1,059
|
426
|
228.5
|
228.5
|
-
|
Enterprise Value (EV)
1 |
476.3
|
487.8
|
814.5
|
950.4
|
324.5
|
179.3
|
213
|
227.6
|
P/E ratio
|
64.9
x
|
-29.2
x
|
-132
x
|
55.4
x
|
-10.7
x
|
-2.51
x
|
-5.94
x
|
-13.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7
x
|
7.74
x
|
9.66
x
|
7.42
x
|
3.04
x
|
2.53
x
|
1.76
x
|
1.42
x
|
EV / Revenue
|
7.13
x
|
7.61
x
|
9.28
x
|
6.66
x
|
2.32
x
|
1.98
x
|
1.64
x
|
1.41
x
|
EV / EBITDA
|
35.5
x
|
-93.8
x
|
112
x
|
26.5
x
|
203
x
|
-3.12
x
|
-21.3
x
|
15.1
x
|
EV / FCF
|
172
x
|
-16.7
x
|
-79.5
x
|
59.4
x
|
-11.2
x
|
-3.6
x
|
-6.46
x
|
-21.7
x
|
FCF Yield
|
0.58%
|
-6%
|
-1.26%
|
1.68%
|
-8.91%
|
-27.8%
|
-15.5%
|
-4.6%
|
Price to Book
|
-
|
-
|
7.3
x
|
5.48
x
|
2.08
x
|
1.59
x
|
1.92
x
|
2.24
x
|
Nbr of stocks (in thousands)
|
66,089
|
76,848
|
82,294
|
86,126
|
96,263
|
100,000
|
100,000
|
-
|
Reference price
2 |
7.072
|
6.450
|
10.30
|
12.30
|
4.425
|
2.285
|
2.285
|
2.285
|
Announcement Date
|
3/14/19
|
5/6/20
|
4/15/21
|
4/20/22
|
4/25/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
66.78
|
64.06
|
87.73
|
142.8
|
140
|
90.47
|
130
|
161
|
EBITDA
1 |
13.4
|
-5.2
|
7.3
|
35.9
|
1.6
|
-57.5
|
-9.982
|
15.03
|
EBIT
1 |
13.92
|
-14.47
|
-5.694
|
20.77
|
-30.22
|
-94.95
|
-42.6
|
-24.72
|
Operating Margin
|
20.84%
|
-22.58%
|
-6.49%
|
14.54%
|
-21.59%
|
-104.95%
|
-32.77%
|
-15.36%
|
Earnings before Tax (EBT)
1 |
5.014
|
-20.89
|
-6.572
|
19.88
|
-45.98
|
-95.95
|
-42.98
|
-18.68
|
Net income
1 |
7.541
|
-16.07
|
-6.245
|
19.01
|
-39.16
|
-89.36
|
-38.86
|
-17.5
|
Net margin
|
11.29%
|
-25.08%
|
-7.12%
|
13.31%
|
-27.97%
|
-98.77%
|
-29.89%
|
-10.87%
|
EPS
2 |
0.1089
|
-0.2210
|
-0.0781
|
0.2220
|
-0.4129
|
-0.9093
|
-0.3848
|
-0.1674
|
Free Cash Flow
1 |
2.765
|
-29.28
|
-10.24
|
15.99
|
-28.91
|
-49.79
|
-32.97
|
-10.47
|
FCF margin
|
4.14%
|
-45.71%
|
-11.67%
|
11.2%
|
-20.65%
|
-55.03%
|
-25.36%
|
-6.51%
|
FCF Conversion (EBITDA)
|
20.63%
|
-
|
-
|
44.55%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
36.67%
|
-
|
-
|
84.13%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/19
|
5/6/20
|
4/15/21
|
4/20/22
|
4/25/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
32.1
|
31.96
|
33.98
|
53.75
|
81.25
|
61.54
|
64.03
|
75.96
|
43.06
|
47.5
|
EBITDA
|
-1.41
|
-3.79
|
-0.398
|
7.7
|
27.09
|
8.808
|
-5.785
|
7.385
|
-33.73
|
-
|
EBIT
1 |
-4.895
|
-9.572
|
-5.766
|
0.072
|
19.66
|
1.11
|
-19.16
|
-11.06
|
-50.75
|
-53.5
|
Operating Margin
|
-15.25%
|
-29.95%
|
-16.97%
|
0.13%
|
24.19%
|
1.8%
|
-29.92%
|
-14.56%
|
-117.85%
|
-112.63%
|
Earnings before Tax (EBT)
1 |
-12.11
|
-8.776
|
-6.126
|
-0.446
|
19.22
|
0.663
|
-27.38
|
-18.59
|
-52.34
|
-51.6
|
Net income
1 |
-10.17
|
-5.898
|
-6.679
|
0.434
|
18.07
|
0.942
|
-25.48
|
-13.67
|
-47.96
|
-48.7
|
Net margin
|
-31.68%
|
-18.45%
|
-19.66%
|
0.81%
|
22.24%
|
1.53%
|
-39.8%
|
-18%
|
-111.37%
|
-102.53%
|
EPS
2 |
-0.1483
|
-0.0727
|
-0.0869
|
0.008800
|
0.2136
|
0.008400
|
-0.2729
|
-0.1400
|
-0.4974
|
-0.4850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/4/19
|
5/6/20
|
9/17/20
|
4/15/21
|
9/22/21
|
4/20/22
|
9/15/22
|
4/25/23
|
9/20/23
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
8.91
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
7.85
|
33.1
|
109
|
102
|
49.2
|
15.5
|
0.94
|
Leverage (Debt/EBITDA)
|
0.6649
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
2.77
|
-29.3
|
-10.2
|
16
|
-28.9
|
-49.8
|
-33
|
-10.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-6.63%
|
12.7%
|
-20%
|
-49.9%
|
-27.4%
|
-17%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-21.5%
|
-9.2%
|
-3.95%
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
415.5
|
422.4
|
442.6
|
Book Value Per Share
2 |
-
|
-
|
1.410
|
2.240
|
2.130
|
1.440
|
1.190
|
1.020
|
Cash Flow per Share
2 |
0.1900
|
-0.0500
|
0.0400
|
0.3000
|
-0.1300
|
-0.5000
|
-0.3200
|
0.0300
|
Capex
1 |
10.1
|
25.8
|
13.4
|
9.46
|
16.3
|
10.9
|
14.7
|
12.8
|
Capex / Sales
|
15.13%
|
40.23%
|
15.23%
|
6.63%
|
11.64%
|
12.01%
|
11.31%
|
7.93%
|
Announcement Date
|
3/14/19
|
5/6/20
|
4/15/21
|
4/20/22
|
4/25/23
|
-
|
-
|
-
|
Last Close Price
2.285
GBP Average target price
3.963
GBP Spread / Average Target +73.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.86% | 285M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|